Patent details
93314
Product Name:
Daclizumab
Basic Information
- Publication number:
- 93314
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
-
EP028028959
- Legal Status:
- Invalid
- Application number:
- 93314
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/16/1107
- Marketing Authorization Type:
-
- Marketing Authorization Date:
- 05/07/2016
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
-
Dates
- Filing date:
- 17/11/2016
- First Marketing Authorization date:
- 05/07/2016
- Grant date:
- 20/11/2019
- Activation date:
- Publication date:
- 20/11/2019
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 08/11/2027
- SPC Extension Expiration:
- 08/11/2027
- Rejection date:
- Withdrawal date:
Owner
- From:
- 17/11/2016
-
-
- Name:
- ABBVIE BIOTECHNOLOGY LTD
- Address:
- CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11, Bermuda (BM)
Agent
1
- Name:
- Dennemeyer & Associates S.A.
- From:
- 17/11/2016
- Address:
- 55, rue des Bruyères, L-1274, HOWALD, Luxembourg (LU)
- To:
2
- Name:
- DENNEMEYER & ASSOCIATES S.A. PATENT DEPARTMENT
- From:
- 17/11/2016
- Address:
- PO Box 1502, 1015, LUXEMBOURG, Luxembourg (LU)
- To:
- 11/10/2019
Inventor
1
- Name:
- SUBRAMANIAN Malathy
- Address:
- United States (US)
2
- Name:
- GUPTA Supriya
- Address:
- United States (US)
3
- Name:
- DUVUR Shanti, G.
- Address:
- United States (US)
4
- Name:
- KAISHEVA Elizabet, A.
- Address:
- United States (US)
Publication
Bulletin
- Bulletin Heading:
- SPC2
- Bulletin edition number:
- 2019/13
- Publication date:
- 20/12/2019
- Description:
- Section D : Granted supplementary protection certificates – I2 publication
Annual Fees
- Annual Fee Due Date:
-
- Annual Fee Number:
-
- Expected Payer:
-
- Last Annual Fee Payment Date:
-
- Last Annual Fee Paid Number:
-
- Payer:
-